Intercept Pharma (ICPT) Tops Q2 EPS by 88c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Intercept Pharmaceuticals (ICPT) PT Lowered to $18 at H.C. Wainwright
August 2, 2021 6:34 AM EDTH.C. Wainwright analyst Ed Arce lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $18.00 (from $21.00) while maintaining a Neutral rating, citing an uncertain road ahead in NASH.
The analyst commented, " As previously expected, the current Ocaliva label issued by the FDA on May 26 establishes new contraindications for patients with: (1) decompensated cirrhosis; (2) a prior decompensation event; or even (3) compensated cirrhosis who have or develop evidence of portal... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $28 at Cowen
July 30, 2021 7:11 AM EDTCowen analyst Ritu Baral lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $28.00 (from $47.00) while maintaining a Market Perform rating.
The analyst commented, "ICPT reported 2Q21 Ocaliva PBC sales of $96.6MM beating consensus ($82.4M). FY21 revenue guidance of $325-$340MM was... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $30 at Needham & Company
July 29, 2021 1:24 PM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $30.00 (from $34.00) while maintaining a Buy rating.
The analyst commented, "ICPT reported 2Q21 financial results today, and we spoke w/ mgmt following the call. Ocaliva (OCA) WW sales of... More
